Announcements

30 July 2024
Onco | Aims and Scope Update

To further enhance the quality of Onco (ISSN: 2673-7523) and the papers published in it, under the guidance of our Editor-in-Chief, Dr. Constantin N. Baxevanis, the journal has updated and revised its aims and scope. The original scope and the updated version are listed below. 

Scope (new version): Scope (old version):
  • Cancer cell signaling;
  • Cancer genetics and molecular targets;
  • Cancer epigenetics and heterogeneity;
  • Carcinogenesis and cancer evolution;
  • Microbiome and cancer;
  • Cancer metabolomics;
  • Cancer biomarkers;
  • Cancer dormancy;
  • Novel targeted and immune cancer therapies;
  • Randomized clinical trials;
  • oncotargets;
  • cancer therapies;
  • clinical reports proposing novel therapeutic regimens.
  • Cancer cell signaling;
  • Cancer genetics and molecular targets;
  • Cancer epigenetics and heterogeneity;
  • Carcinogenesis and cancer evolution;
  • Microbiome and cancer;
  • Cancer metabolomics;
  • Cancer biomarkers;
  • Cancer dormancy;
  • Novel targeted and immune cancer therapies;
  • Randomized clinical trials.

 For more detailed information, please visit the following link: https://www.mdpi.com/journal/onco/about. 

Onco Editorial Office

More News...
Back to TopTop